Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology

Gentium S.p.A. (Nasdaq: GENT) (the "Company") today announced that two posters and one oral presentation on defibrotide will be presented at the 33rd World Congress of International Society of Hematology to be held at the ICC Jerusalem International Convention Center in Jerusalem, Israel, October 10-13, 2010.

Poster Session 1, Tuesday, October 12, 2010:

"Defibrotide downregulates heparanase expression in tumor cells" (Abstract #330). C. Echart et. al., Gentium SpA, Como, Italy.

"Defibrotide protects endothelial cells from the complications of stem cell transplantation" (Abstract #335). C. Echart et al., Gentium SpA, Como, Italy.

Oral Presentation, Hall A, Wednesday, October 13, 2010:

"Defibrotide prevents acute Graft-versus-Host disease in pediatric stem cell transplantation: results of the prospective phase II/III VOD-DF trial" (Abstract #386, ). S. Corbacioglu et al., University of Regensburg, Germany.

SOURCE Gentium S.p.A.